Clinical trials: TACE, completed
Carcinoma, Hepatocellular, Cirrhosis
Expansion of Conventional Criteria for Liver Transplantation in Hepatocellular Carcinoma Through Downstaging
This clinical trial is aimed at extending the chance of liver transplantation, through downstaging procedures, to patients with hepatocellular carcinoma (HCC) exceeding conventional Milan Criteria.
- Trial name
- NCT01387503
- Testing
- Liver transplantation
- Where
- 10 sites in Italy
- Volunteers
- 74 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Hepatocellular Carcinoma Non-resectable
Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma
Pivotal Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma
- Trial name
- NCT03533920
- Testing
- UNI-DEB
- Where
- 8 sites in South Korea
- Volunteers
- 62 people
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma (HCC)
Can Quantitative MRI After cTACE Help Predict Survival ?
Transcatheter arterial chemoembolization (TACE) is a widely accepted palliative therapy for the treatment of HCC. Palliative means that it does not cure the disease prolongs your life and improves quality of life.
- Trial name
- NCT02173119
- Testing
- MRI post-TACE
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Medical College of Wisconsin
Liver Cancer
A Study of Avastin (Bevacizumab) and Transarterial Chemoembolisation (TACE) Treatment in Patients With Liver Cancer
This single-arm, open-label study assessed the efficacy and safety of Avastin (bevacizumab) treatment combined with transarterial chemoembolisation (TACE) in patients with localized unresectable liver cancer.
- Trial name
- NCT00576199
- Testing
- Bevacizumab, Transarterial chemoembolisation (TACE)
- Where
- 3 sites in Hong Kong
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma
Efficacy and Safety of TACE in Combination With ICIs for HCC: a Real-world Study
The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) in patients with hepatocellular carcinoma (HCC) .
- Trial name
- CHANCE001 (NCT04975932)
- Testing
- TACE+ICIs, TACE
- Where
- China
- Volunteers
- 826 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma
Comparison of Two Solvents Used With Chemotherapy Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma
TACE is considered the standard treatment for unresectable HCC and is widely used as a palliative treatment. However there is no consensus of the protocol of TACE.One of the variation is does the stability of the suspension by…
- Trial name
- NCT01259414
- Testing
- Solvent with specific gravity less than lipiodol, Solvent with specific gravity equivalent to lipiodol
- Where
- China
- Volunteers
- 812 people
- Sponsor
- Sun Yat-sen University
Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Preoperative Transarterial Chemoembolization for Resectable HCC With Portal Venous Invasion
Whether preoperative transarterial chemoembolization can prolong survival for the resectable hepatocellular carcinoma remains controversial, particularly in patients with portal vein tumor thrombi.
- Trial name
- NCT01952353
- Testing
- Preoprative TACE, Liver resection plus Thrombectomy
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Hepatocellular
Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas
The purpose of this study is to determine the maximal tolerated dose of idarubicin for chemoembolization of non resectable non metastatic hepatocellular carcinoma.
- Trial name
- NCT01040559
- Testing
- idarubicin
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization
Postoperative TACE(Transhepatic Arterial Chemotherapy And Embolization) for Patients With Hepatocellular Carcinoma
1. Hepatocellular carcinoma (HCC) is the most common primary malignancy of liver, representing the third leading cause of cancer-related death worldwide. 2.
- Trial name
- NCT02109146
- Testing
- Prophylactic Transcatheter Arterial Chemoembolization, Observation
- Where
- China
- Volunteers
- 332 people
- Sponsor
- Zhejiang University
Hepatocellular Carcinoma Non-resectable
Pilot Clinical Trial to Evaluate the UNI-DEB for Unresectable Hepatocellular Carcinoma
Pilot Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma
- Trial name
- NCT03564405
- Testing
- UNI-DEB
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With TACE in Unresectable Hepatocellular Carcinoma
This Phase Ia study evaluated the safety and tolerability of a single escalating dose via intravenous infusion of the autologous invariant natural killer T cells (iNKT-cell) product GKL-006 in combination with transarterial…
- Trial name
- NCT07845266
- Testing
- GKL-006 Injection, transarterial chemoembolization
- Where
- 2 sites in China
- Volunteers
- 13 people
- Sponsor
- Beijing Gene Key Life Technology Co., Ltd
Neuroendocrine Tumor, Malignant, Liver Metastases
Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver
The primary aim of this trial is to estimate the duration of hepatic progression-free survival (HPFS) in participants treated with bland embolization (BE), transcatheter arterial Lipiodol chemoembolization (TACE), and…
- Trial name
- NCT02724540
- Testing
- Bland Embolization, Transarterial chemoembolization, Drug Eluting Beads Embolization
- Where
- 13 sites in United States, Argentina and 2 more
- Volunteers
- 162 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Hepatocellular Carcinoma
Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular Carcinoma
The purpose of this study is to determine whether neoadiuvant therapy with sorafenib increases the efficacy of thermal ablation in inducing the necrosis of hepatocellular carcinoma.
- Trial name
- LANEX (NCT01507064)
- Testing
- Sorafenib, laser ablation (LA)
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Cardarelli Hospital
Hepatocellular Cancer
Interest of elastoFRM With Force Measure by MRI on Patients With Hepatocellular Cancer
FORCE project aims to measure actives forces of malignant tumor by magnetic resonance force (FRM). Two main forces are considered as key indicators of therapeutic response and metastatic potential: interstitial force and traction…
- Trial name
- FORCE (NCT02929082)
- Testing
- IRM with a 5-minute- additional sequence to measure FRM
- Where
- France
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma
Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma
Systemic therapy is the primary option for managing advanced hepatocellular carcinoma (HCC). The combination of atezolizumab and bevacizumab (A+B) has emerged as the first-choice treatment for advanced HCC(IM brave 150).
- Trial name
- NCT06199297
- Testing
- Atezolizumab combined with Bevacizumab, Sintilimab combined with Bevacizumab, Transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Hepatocellular Carcinoma by BCLC Stage
Volumetric Analysis of Hepatocellular Carcinoma After Transarterial Chemoembolization
The application of transarterial chemoembolisation (TACE) with drug-eluting beads in patients with hepatocellular carcinoma and its response to the treatment will be observed.
- Trial name
- NCT04780789
- Testing
- Transarterial Chemoembolization
- Volunteers
- 61 people
- Sponsor
- Brno University Hospital
Clinically Significant Portal Hypertension
The Effect of Sorafenib on Portal Pressure
Sorafenib is approved by the US FDA for the treatment of unresectable (can not operate) liver cancer and for renal cell carcinoma.
- Trial name
- NCT01714609
- Testing
- Sorafenib
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- Yale University
Unresectable Intrahepatic Cholangiocarcinoma
Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
The purposed of this research is to study the safety and clinical activity of the combination of durvalumab and a CSF-1R inhibitor (SNDX-6352) in people with Intrahepatic Cholangiocarcinoma.
- Trial name
- NCT04301778
- Testing
- Durvalumab, SNDX-6352
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lung Metastases, Endobronchial Metastases
Chemoembolization for Lung Tumors
This study is being done to determine if it is safe to perform lung chemoembolization and if the lung chemoembolization procedure can successfully deliver chemotherapy to lung tumors.
- Conditions
- Lung Metastases, Endobronchial Metastases, Pleural Metastases, Mediastinal Metastases
- Trial name
- NCT04200417
- Testing
- Chemoembolization, Mitomycin C, Lipiodol
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma, Malignant Neoplasm
Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical Resection
The purpose of this study is to assess the efficacy and safety of combining autologous Tcm immunotherapy and TACE in HCC patients with MVI after radical resection.
- Trial name
- NCT03575806
- Testing
- TACE plus autologous Tcm immunotherapy, TACE
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences